Mosunetuzumab
Nodular Lymphocyte Predominant B-Cell Lymphoma
National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Nodular Lymphocyte Predominant B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 National Cancer Institute (NCI) | Phase 3 | BBB |
PREDNISONE TABLETS National Cancer Institute (NCI) | Phase 3 | BBB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | BB |
FILGRASTIM Children's Oncology Group | Phase 3 | BB |
(+)-VINCRISTINE Children's Oncology Group | Phase 3 | BB |
View all 30 →
Same molecule, other indications
Mosunetuzumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →